SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICN Pharmaceuticals
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Clouseau who wrote (785)3/26/1998 8:50:00 AM
From: IRWIN JAMES FRANKEL  Read Replies (1) of 1029
 
I have followed ICN for some time and don't believe the buyout case. It seemed to me that the most likely companies could easily have purchased this company much cheaper a year ago. SGP and Roche (each with interferon A products are ideal) each have contracts with ICN and my guess is that they have stand still agreements in those contracts that prevent an offer for ICN unless it is in play. Once in play (should that happen) spirited bidding could occur. SGP would want to gain Europe to distribute Intron A (as part of combo therapy) and Roche to keep their interferon A product in the running in Europe where they are stronger than SGP. But this concept requires a company to start ICN play. So far I dont see that since they would know they would have a fight with Roche and SGP, who have a lot to gain that 3rd parties would not.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News